Foundation Medicine Inc (FMI.OQ)
136.40USD
1:30am IST
$-0.05 (-0.04%)
$136.45
$136.40
$136.50
$136.40
135,513
132,760
$137.10
$31.70
About
Overall
| Beta: | -0.09 |
| Market Cap(Mil.): | $1,689.42 |
| Shares Outstanding(Mil.): | 36.02 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.
BRIEF-Foundation Medicine Q1 Loss Per Share $1.02
* FOUNDATION MEDICINE ANNOUNCES 2018 FIRST QUARTER RESULTS AND RECENT HIGHLIGHTS
BRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La Roche
* SAYS IT SIGNS SEPARATE AGREEMENTS WITH FOUNDATION MEDICINE INC, F. HOFFMANN-LA ROCHE LTD ON TUMOUR TREATMENT Source text in Chinese: https://bit.ly/2FlRDHB Further company coverage: (Reporting by Hong Kong newsroom)
BRIEF-Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By U.S. FDA
* FOUNDATION MEDICINE'S NEW LIQUID BIOPSY ASSAY GRANTED BREAKTHROUGH DEVICE DESIGNATION BY U.S. FOOD AND DRUG ADMINISTRATION
BRIEF-Foundation Medicine - Co, Guardant Health Announced Agreement To Settle False Advertising Challenges
* FOUNDATION MEDICINE - CO, GUARDANT HEALTH ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Foundation Medicine Reports Qtrly loss Per Share $1.05
* FOUNDATION MEDICINE ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS, RECENT HIGHLIGHTS AND 2018 OUTLOOK
BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd
* FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING
BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO
BRIEF-Foundation Medicine Reports Preliminary 2017 Results
* - PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE
BRIEF-Foundation Medicine Files For Potential Mixed Shelf, Size Not Disclosed
* FOUNDATION MEDICINE INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2BO42UB) Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Roche Holding Ltd. (ROG.S) | CHF216.45 | -- |
| Roche Holding Ltd. (RO.S) | CHF219.60 | -1.20 |
| Abbott Laboratories (ABT.N) | $61.75 | -0.39 |
| Quest Diagnostics Inc (DGX.N) | $111.18 | +0.46 |
| Laboratory Corp. of America Holdings (LH.N) | $187.58 | +0.41 |
| Qiagen NV (QGEN.N) | $36.21 | -0.22 |
| Bio-Reference Laboratories Inc (BRLI.OQ) | -- | -- |
| Myriad Genetics, Inc. (MYGN.OQ) | $38.69 | -0.36 |
| Genomic Health, Inc. (GHDX.OQ) | $51.38 | -0.50 |
| Sequenom, Inc. (SQNM.OQ) | -- | -- |
Estimates